The Filing Desk

C4 Therapeutics vs Kymera Therapeutics

C4 Therapeutics CCCC · Kymera Therapeutics KYMR · Biotechnology

Kymera Therapeutics reported revenue of $39 million in fiscal 2025, about the same as C4 Therapeutics' $36 million in fiscal 2025. C4 Therapeutics' revenue grew 1.0% in its latest year, and Kymera Therapeutics' fell 16.7%. C4 Therapeutics had an operating margin of -320.5%, against -891.1% at Kymera Therapeutics. Free cash flow was −$99 million at C4 Therapeutics and −$234 million at Kymera Therapeutics.

Side by side

C4 TherapeuticsKymera Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$36M$39M
Revenue growth1.0%−16.7%
Revenue growth a year, last 5 years—2.9%
Gross margin—0.0%
Operating margin−320.5%−891.1%
Net margin−292.1%−794.0%
Free cash flow−$99M−$234M
Free cash flow margin−276.2%−597.6%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count19.5%12.6%
Last close$2.44$119.39
P/E at the last close——
Insider trades, last 12 monthssold $22,200bought $172.5 million, sold $461.2 million
Piotroski F-score3 of 8—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
C4 TherapeuticsKymera Therapeutics
Operating margin
Percent of revenue
C4 TherapeuticsKymera Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
C4 TherapeuticsKymera Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the C4 Therapeutics and Kymera Therapeutics pages.